Search

everythinglearnresearchcommunity

for

Search:↓

A 22-year-old trans woman has been on 6mg estradiol enanthate for five months. She reports thicker and healthier hair but not much regrowth yet.

Treating hair loss with various remedies, such as Cetirizine and the Big3 complex (minoxidil, finasteride, and RU58841), which have properties like adipogenic, anti-fibrotic and anti-inflammatory. References to research studies are also included.

Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

Exosome injections stimulate hair growth by using exosomes' healing potential to awaken dormant hair follicles and promote new hair cell creation. The procedure increases scalp blood circulation, encourages collagen and elastin formation, and regenerates hair follicles, improving hair thickness and quality.

Hair loss discussion mentions ineffective treatments like Nutrafol and low-level laser therapy sold by transplant clinics. Trust in hair restoration doctors questioned due to promoting these treatments.

The user plans to enhance their hair loss treatment with oral minoxidil, finasteride tablets, laser cap therapy, and various supplements. They are also considering a hair transplant and exploring reputable sources for these products.

Increasing the sult1a1 enzyme on the scalp may improve response to topical minoxidil. The user suggests using a baking soda solution, DMSO, and tretinoin to enhance enzyme activity and minoxidil effectiveness.

The conversation discusses an extensive hair loss treatment regimen including dutasteride, GT20029, RU58841, pyrilutamide, minoxidil, microneedling, ketoconazole shampoo, and experimental compounds. The user humorously describes their approach as a comprehensive strategy to combat hair loss while maintaining hair growth.

User considers adding Alfatradiol to their topical finasteride treatment for hair loss. Others discuss Alfatradiol as a weak estrogen and 5α-reductase inhibitor used for pattern hair loss in men and women.

Hair loss treatments include topical and oral minoxidil, low-level laser light therapy, and peptide serums. Bryan Johnson avoids finasteride and dutasteride due to potential side effects, focusing instead on his own protocol with these treatments.

A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.

The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.

The user is using minoxidil, finasteride, dermarolling, and other treatments for hair regrowth, showing promising results in the temple area. Despite some skepticism, there is optimism about potential improvement.

User experienced positive results with CosmeRNA for hair loss after 1.5 weeks, including reduced scalp itchiness, less oiliness, and decreased shedding. They have not felt any side effects and are happy with the treatment so far.

The post discusses a hair loss treatment regimen using saw palmetto, pumpkin seed oil extract, EGCG (green tea) extract, grape seed oil extract, rosemary oil extract, and Zix. The user plans to use these DHT-blockers and 5AR inhibitors for six months and report the results.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

A human trial involving the use of Verteporfin as a treatment for hair loss, which has been ongoing for 119 days with an update on its progress. Treatments such as Minoxidil, Finasteride and RU58841 have also been discussed.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

A trans woman is using finasteride, minoxidil, microneedling, and HRT to address hair loss, with noticeable improvement in hairline shape and presence of vellus hairs. She is considering hair transplants if these treatments don't yield desired results within a year or two.

The conversation discusses the use of Verteporfin in hair loss treatment. It suggests that Verteporfin could potentially regenerate hair follicles instead of forming scars, providing an unlimited donor supply for hair transplants.

The user experienced temporary peach fuzz growth using a product with procapil and later tried minoxidil and finasteride without significant results. Their boyfriend has used minoxidil and finasteride consistently for over five years with sparse hair improvement.

The user is experiencing significant hair loss and has tried treatments like PRP therapy, topical and oral Minoxidil, Finasteride, and dietary changes, with limited success. They are concerned about losing more hair before a scheduled hair transplant and are advised to postpone the transplant to allow medications more time to work.

User experienced feminizing side effects from finasteride and tried RU, alfatradiol, and finasteride without success. They are now considering treatments like Stemoxydine, Zix, Minoxidil, Dermarolling, Eucapil, and a hair transplant.

Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.

New company Amplifica receives $11.8 million for hair loss product development, co-founded by Dr. Maksim Plikus and William Rassman. Users discuss undisclosed product candidates and application methods.

The conversation discusses the use of 5-alpha-reductase inhibitors like finasteride and dutasteride for hair loss in transgender women, particularly in relation to testosterone suppression. The original poster has been using dutasteride and is considering stopping it due to undetectable testosterone levels.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.

Low-Level Laser Therapy (LLLT) is seen as a safe and effective method for maintaining hair and promoting regrowth in androgenetic alopecia (AGA) and male pattern baldness (MPB), with devices like the HairMax LaserComb® and iRestore helmet being popular. Some users and professionals are skeptical about its long-term effectiveness and cost.